Clinical Trial Update: Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apixaban for efficacy and safety in heparin-induced thrombocytopenia (HIT); study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heparin-induced Thrombocytopenia
• Heparin-induced Thrombocytopenia and Thrombosis

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis | Phase 2 | Status: TERMINATED | Results posted: 2020-12-23